TEST:

SeekInClarity®

"SeekIn Inc...announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE."

"SeekIn Inc...announces its participation in the prestigious ASCO Breakthrough Conference. The event takes place in Yokohama Japan on August 3-5, 2023...The second abstract presents a prospective study that utilizes SeekInClarity®, a pan-cancer, non-invasive efficacy detection technology, to evaluate treatment response and prognosis prediction in lymphoma patients."

"SeekIn Inc...announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States...study presents a strong demonstration that SeekInClarity can be considered an in vivo drug sensitivity test."

The dynamic change of MTB exhibited a good prognostic power of lymphoma. It challenged the status quo of employing imaging as a sole standard for evaluating early treatment response.

This prospective study demonstrated SeekInClarity, a non-invasive, multidimensional bloodbased assay, can promptly evaluate the treatment response of lymphoma patients, and showed an excellent correlation between MTB status and the clinical outcome. It challenged the status quo of employing imaging as a sole standard for evaluating early treatment response.

"SeekIn said...that it has received CE marking for its SeekInClarity Cancer Treatment Response Monitoring Kit...The Shenzhen, China-based biotech said that it is now ready to launch the kit in Europe and other countries that recognize the CE mark...The liquid biopsy assesses cancer treatment response through changes in circulating tumor DNA."

This proof-of-concept study demonstrated SeekInClarity, a non-invasive, multidimensional multi-omics blood-based assay, can promptly evaluate the treatment response of patients with lymphoma. By implementing this assay, the dynamic change of MTB can help physicians to make well-informed decisions on the upcoming therapeutic strategies for each patient in conjunction with imaging. This study is still ongoing, and more cases and more time points are included to demonstrate the clinical performance of the assay.